ChiCTR2400081107 版本V1.0 版本创建时间2024/02/22 15:29:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400081107 

最近更新日期:

Date of Last Refreshed on:

2024-02-22 15:29:40 

注册时间:

Date of Registration:

2024-02-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脑损伤患者合并症、并发症、功能预后等相关因素回顾性临床研究方案

Public title:

A retrospective clinical study of comorbidities, complications, functional prognosis and other related factors in patients with brain injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脑损伤患者合并症、并发症、功能预后等相关因素:回顾性临床研究

Scientific title:

Comorbidities, complications, functional prognosis and other related factors in patients with brain injury: Retrospective clinical study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

成贵卿 

研究负责人:

袁华 

Applicant:

Cheng Guiqing 

Study leader:

Yuan Hua 

申请注册联系人电话:

Applicant telephone:

+86 153 4927 7713

研究负责人电话:

Study leader's
telephone:

+86 136 5919 2988

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

anchenggq@163.com

研究负责人电子邮件:

Study leader's E-mail:

yuanhua@fmmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

陕西省西安市新城区长乐西路169号

研究负责人通讯地址:

陕西省西安市新城区长乐西路169号

Applicant address:

169 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province

Study leader's address:

169 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

空军军医大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Air Force Medical University

研究负责人所在单位:

空军军医大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Air Force Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY20232243-C-1号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军空军军医大学第一附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First Affiliated Hospital of Air Force Medical University of the People's Liberation Army

伦理委员会批准日期:

Date of approved by ethic committee:

2023-08-11 00:00:00

伦理委员会联系人:

贾艳艳

Contact Name of the ethic committee:

Jia Yanyan

伦理委员会联系地址:

陕西省西安市新城区长乐西路127号

Contact Address of the ethic committee:

127 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 29 8477 1794

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

空军军医大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Air Force Medical University

研究实施负责(组长)单位地址:

陕西省西安市新城区长乐西路127号

Primary sponsor's address:

127 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西

市(区县):

西安

Country:

China

Province:

Shannxi

City:

Xi‘an

单位(医院):

空军军医大学第一附属医院

具体地址:

陕西省西安市新城区长乐西路127号

Institution
hospital:

The First Affiliated Hospital of Air Force Medical University

Address:

127 Changle West Road, Xincheng District, Xi 'an City, Shaanxi Province

经费或物资来源:

空军军医大学

Source(s) of funding:

Air Force Medical University

研究疾病:

脑损伤  

Target disease:

Brain injury

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

明确脑损伤患者并发症、合并症、功能预后等的相关因素,明确脑损伤患者并发症、合并症的流行病学特点。  

Objectives of Study:

To clarify the related factors of complications, comorbidities and functional prognosis in patients with brain injury, and to clarify the epidemiological characteristics of complications and comorbidities in patients with brain injury.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合中华神经科学会标准中脑损伤相关疾病的诊断标准; 2.经影像学检查证实存在脑卒中、脑外伤、缺血缺氧性脑病等器质性损害。

Inclusion criteria

1. Conforming to the criteria of brain injury-related diseases in the standard of the Chinese Neurological Association; 2. It was confirmed by imaging examination that there were organic lesions such as stroke, brain trauma , and ischemic hypoxic encephalopathy.

排除标准:

1.年龄<18岁; 2.伴有严重心、肺等重要脏器疾病患者; 3.临床资料不完整者。

Exclusion criteria:

1. Age < 18 years old; 2. Patients with serious heart, lung, and other important organ diseases; 3. Incomplete clinical data.

研究实施时间:

Study execute time:

From 2023-08-01 00:00:00 To 2033-08-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-03-01 00:00:00 To 2033-07-01 00:00:00

干预措施:

Interventions:

组别:

根据是否发生并发症、合并症分组

样本量:

2124

Group:

Grouping according to the occurrence of complications and comorbidities

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

陕西 

市(区县):

西安 

Country:

China

Province:

Shannxi

City:

Xi'an

单位(医院):

空军军医大学第一附属医院 

单位级别:

三甲 

Institution
hospital:

The First Affiliated Hospital of Air Force Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Brunnstrom分期

指标类型:

主要指标

Outcome:

Brunnstrom stage

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Fugl-Meyer运动评分

指标类型:

主要指标

Outcome:

Fugl-Meyer assessment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良Barthel评分

指标类型:

主要指标

Outcome:

Modified-Barthel index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

静脉血栓、神经病理性疼痛、营养不良等的发生率

指标类型:

主要指标

Outcome:

The incidence of venous thrombosis, neuropathic pain, malnutrition, etc

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

用药情况

指标类型:

主要指标

Outcome:

Medication situation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

危险因素

指标类型:

主要指标

Outcome:

Risk factors

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究结果发表后在ResMan上共享(www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The findings will be shared on ResMan after publication (www.medresman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表;评估表;电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form; Evaluation form; EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-02-22 15:29:40